InSysBio to participate in ACoP14

October 26, 2023

InSysBio announces its participation in the Fourteenth American Conference on Pharmacometrics (ACoP14) which is to be held from November 5-8, 2023, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, USA. The theme of ACoP14 is “Innovation & Diversity: Redefining Pharmacometrics”. InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #6 and 10 posters in frames of the Conference, namely:

Monday, November 6:

  • M-008 "fIVE DB Calculator: web application for parameter calculation from in vitro data" by Alexander Stepanov, Oleg Demin
  • M-010 "Modeling of the effects of IFNγ and TNFα release on pharmacokinetics of a bispecific antibody against PD1 and CD40" by Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
  • M-066 "Calculation of PD-L1 dissociation constant using available gel filtration experimental data" by Ekaterina Goryacheva, Oleg Demin
  • M-067 "fIVE DB as a tool to collect data from in vitro experiments and automatically calculate kinetic parameters: focus on impact of experimental conditions" by Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin
  • M-111 "Secure and scalable computational environment for QSP modeling and simulations" by Ivan Borisov, Evgeny Metelkin 

Tuesday, November 7:

  • T-073 "Analytical approaches to optimize structure and reduce complexity of QSP models: focus on immuno-oncology" by Maria Mironovich, Julia Sergienko, Oleg Demin
  • T-111 "QSP modeling efficacy of nilotinib on pathologic proteins in Parkinson’s disease" by Tatiana Karelina, Olga Ivanova, Oleg Demin
  • T-112 "Development and Validation of a QSP Model of Synovial Sarcoma Treatment with Lete-cel: Implementation of ORR and PFS" by Oleg Demin Jr1, Galina Kolesova2, Dmitry Shchelokov1, Stefan Zajic3, Lourdes Cucurull-Sanchez

Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Wednesday, November 8:

  • W-076 "Translational PK/RO model of tetravalent bispecific antibody CTX8371: effect of bispecific binding and multimeric complexes formation on the PD1 and PDL1 receptor occupancy" by Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
  • W-077 "QSP model of neutrophils depletion during Sarilumab treatment constructed from Immune Response template submodels" by Veronika Musatova, Oleg Demin, Anna Viktorenko

Check out our Booth#6 at ACoP14!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit